Cough & Cold Medicine Manufacturing OTC in the US - Industry Market Research Report

Take Two: Industry Demand Will Continue to Increase Due to Rising Online Sales

Companies in the Cough and Cold Medicine Manufacturing OTC industry have benefited from increasing consumers purchasing over-the-counter (OTC) medications to address ailments with at-home treatments. The COVID-19 pandemic has been the most prominent proponent for industry demand. In 2020 industry revenue increased as consumers stockpiled industry products to address symptoms and potential infection with the fear of a new COVID-19 variant. Overall, industry-wide revenue has been growing at a CAGR of 5.6% over the past five years and is expected to total $12.0 billion in 2023, when payment will jump by an estimated 8.6%. Similarly, unprecedented demand will precipitate and keep profit elevated.

This industry manufactures over-the-counter (OTC) cough and cold treatments and suppressants. Products include systemic remedies, such as antihistamines and combination products, decongestants and medicated candies. The industry does not include companies that are primarily retailers, such as pharmacies or department stores.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry's key players and their market shares.